Review3 Biotech2023
Vascular endothelial growth factor-C and its receptor-3 signaling in tumorigenesis.
Review in 3 Biotech, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 15 citations in OpenAlex.
- Article
- The meningeal lymphatic vessel-peripheral immune axis: a novel therapeutic target in neurodegenerative diseases.Journal of neuroinflammation · 2026Review
- Non-anticoagulant heparins: glycan-mediated immune modulation and therapeutic applications.Frontiers in immunology · 2026Review
- Long non-coding RNAs and VEGF in ovarian cancer: mechanisms and therapeutic potential.Journal of ovarian research · 2025Review
- Analysis of research hotspots on the detection of vascular endothelial growth factor C and its receptor vascular endothelial growth factor receptor-3 in cervical squamous cell carcinoma.Discover oncology · 2025Article
- Mendelian randomization analysis reveals causal roles of inflammatory cytokines in thyroid cancer pathogenesis.Discover oncology · 2025Article
- Exploration of the mechanism of Polyphyllin I against hepatocellular carcinoma based on network pharmacology, molecular docking and experimental validation.Discover oncology · 2025Article
- VEGF-C and Lymphatic Vessel Density in Tumor Tissue of Gastric Cancer: Correlations with Pathoclinical Features and Prognosis.Cancers · 2025Article
- Characterization of hepatocarcinoma cells: lymphatic metastasis potential through enhanced production, expression, and secretion along the VEGF-C/D-VEGFR-3/NRP-2 axis.Discover oncology · 2025Article
- Association of serum vascular endothelial growth factor-C, vascular endothelial growth factor receptor-3, and insulin-like growth factor 1 levels with metastasis and prognosis in patients with nasopharyngeal carcinoma.Frontiers in oncology · 2025Article
- Lymphatic metastasis of papillary thyroid carcinoma: mechanism and clinicopathological physiology.Frontiers in endocrinology · 2025Review
- Bioinformatics analysis revealsTranslational cancer research · 2024Article
- Structural and dynamical insights revealed the anti-glioblastoma potential of withanolides from Withania coagulans against vascular endothelial growth factor receptor (VEGFR).Journal of molecular modeling · 2024Article
- ZNF468-mediated epigenetic upregulation of VEGF-C facilitates lymphangiogenesis and lymphatic metastasis in ESCC via PI3K/Akt and ERK1/2 signaling pathways.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- New Interpretations for Sprouting, Intussusception, Ansiform, and Coalescent Types of Angiogenesis.International journal of molecular sciences · 2024Review
- Case report: Successful therapy with recombinant human vascular endostatin in an elderly man with colon telangiectasia and idiopathic thrombocytopenic purpura.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cancer-promoting ligand vascular endothelial growth factor-C (VEGF-C) activates VEGF receptor-3 (VEGFR-3). The VEGF-C/VEGFR-3 axis is expressed by a range of human tumor cells in addition to lymphatic endothelial cells. Activating the VEGF-C/VEGFR-3 signaling enhances metastasis by promoting lymphangiogenesis and angiogenesis inside and around tumors. Stimulation of VEGF-C/VEGFR-3 signaling promotes tumor metastasis in tumors, such as ovarian, renal, pancreatic, prostate, lung, skin, gastric, colorectal, cervical, leukemia, mesothelioma, Kaposi sarcoma, and endometrial carcinoma. We discuss and update the role of VEGF-C/VEGFR-3 signaling in tumor development and the research is still needed to completely comprehend this multifunctional receptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.